Fox Run Management L.L.C. Makes New Investment in Intuitive Surgical, Inc. $ISRG

Fox Run Management L.L.C. purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,824 shares of the medical equipment provider’s stock, valued at approximately $1,263,000.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock valued at $15,026,776,000 after purchasing an additional 263,828 shares during the period. State Street Corp lifted its holdings in Intuitive Surgical by 1.2% in the 2nd quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock worth $8,451,223,000 after buying an additional 182,871 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Intuitive Surgical by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock worth $4,429,590,000 after buying an additional 109,904 shares in the last quarter. Norges Bank purchased a new position in Intuitive Surgical in the 2nd quarter valued at about $2,569,260,000. Finally, Invesco Ltd. grew its stake in shares of Intuitive Surgical by 4.8% during the second quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock valued at $2,402,488,000 after acquiring an additional 201,159 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $506.17 on Thursday. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $603.88. The company’s 50 day simple moving average is $532.31 and its 200 day simple moving average is $511.29. The firm has a market capitalization of $179.76 billion, a PE ratio of 64.15, a P/E/G ratio of 3.83 and a beta of 1.65.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. The business had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.21 EPS. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gary S. Guthart sold 2,800 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $531.52, for a total value of $1,488,256.00. Following the completion of the sale, the director directly owned 15,720 shares of the company’s stock, valued at approximately $8,355,494.40. This represents a 15.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 464 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the completion of the sale, the senior vice president directly owned 131 shares of the company’s stock, valued at approximately $71,852.19. This trade represents a 77.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 56,189 shares of company stock worth $30,785,441. 0.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ISRG has been the subject of a number of recent analyst reports. Argus lowered their price objective on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Royal Bank Of Canada increased their target price on Intuitive Surgical from $625.00 to $650.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. BTIG Research restated a “buy” rating and issued a $616.00 price target on shares of Intuitive Surgical in a research note on Friday, January 23rd. Wells Fargo & Company upped their price target on shares of Intuitive Surgical from $600.00 to $654.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, Raymond James Financial increased their price objective on shares of Intuitive Surgical from $603.00 to $615.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $615.86.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.